O'Reilly Automotive (ORLY)
$465.18 0.89 (0.19%)
18:15 EDT ORLY Stock Quote Delayed 30 Minutes
Previous Close $465.18
Market Cap 38.10B
PE Ratio 34.59
Volume (Avg. Vol.) 454,200
Day's Range 462.69 - 469.73
52-Week Range 251.51 - 487.95
Dividend & Yield N/A (N/A)
ORLY Stock Predictions, Articles, and O'Reilly Automotive News
- From InvestorPlace
- From the Web
Although a disconnect currently exists between the stock market and the rest of the economy, this may not last. Therefore, it’s better to be prepared with these recession-resistant stocks to buy.
Tuesday's big stock charts focus on the positive, and feature three names that managed to eke out a gain despite Monday's market rout.
Seemingly every day, the fundamentals surrounding the U.S. economy seem to deteriorate. Nevertheless, these services-related stocks to buy offer a contrarian way to profit from the weakness.
The stock charts of STX, ORLY and MCK are headed into the middle of the week on the verge of significant moves.
Retail stocks have under-performed year-to-date, but Goldman Sachs thinks this depressed group of stocks is ready to rebound in a big way.
O’Reilly Automotive (ORLY) stock is looking dreary after disappointing earnings, but it's far from doomed. Here's what you should know before you buy.
It’s hard to find companies closing wage gap between employees and CEO -- but you can buy stocks with a lower pay ratio to win long term.
The stock charts of ORLY, NEM and MAS look better positioned to make trade-worthy moves this week than most other names.
Not all stocks lost out in 2018. These are the strong-buy stocks that emerged victorious from a year of extremely volatile trading.
These 12 stocks gained nicely in 2018 -- but they're stocks to sell in 2019.
Chances are, the volatility of the 2018 markets isn't going anywhere. But Goldman Sachs is here to help with these top stock picks for 2019.
US-Mexico trade pact gives American auto plants an upper hand over Mexican facilities, where workers earn far less. Railroads also gain as the deal eases risks....
AutoZone stock far and away looks like the best play in the auto parts sector. The question is whether that sector is safe enough to confidently own AZO stock for the mid- to long-term.
3 Stocks to Watch on Thursday: Allstate Corp (ALL), Twenty-First Century Fox Inc (FOXA) and O’Reilly Automotive Inc (ORLY)
Allstate (ALL), Twenty-First Century Fox (FOXA) and O'Reilly Automotive (ORLY) all reported on their latest quarterly earnings after the bell Wednesday.
Shares of auto parts companies bounced back hard in the second half of 2017, and particularly ORLY stock could have plenty more upside left.
The long-term chart of AZO stock is broken but in the nearer-term a trading opportunity looks to be setting up in AutoZone.
These three retail stocks are continuing the dark narrative surrounding the industry. Here's what you need to know about each.
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
ESSA Pharma (EPIX -1.5%) announces the closing of an underwritten public offering of 7,100,000 shares at a price of $6 per share.The underwriters were granted a 30-day option to purchase up to an additional 1,065,000 common shares, and the underwriters exercised the option on July 29, 2020.The proceeds from the offering were ~$45M after deducting underwriting discounts and commissions.Net proceeds to be used for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes.Jefferies acted as sole book-running manager.
From Analyst Ratings
In a report released today, Mark Breidenbach from Oppenheimer reiterated a Buy rating on ESSA Pharma (EPIX – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $5.40, close to its 52-week high of $6.14. According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 12.2%
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
Navellier RatingsPowered by Portfolio Grader